92 results
Page 3 of 5
8-K
EX-99.1
gih1ubtqv2fuaea
3 Nov 21
Arvinas Reports Third Quarter 2021 Financial Results and Provides Corporate Update
4:01pm
424B5
bh9sh x37lsuq76
6 Aug 21
Prospectus supplement for primary offering
4:34pm
8-K
EX-99.1
0s1 zlqmx1mdfkpw
5 Aug 21
Arvinas Reports Second Quarter 2021 Financial Results and Provides Corporate Update
4:02pm
8-K
EX-99.2
gwacdsqfg29zf
22 Jul 21
Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC® Protein
7:30am
8-K
EX-99.1
6m2h 4gd897npm
22 Jul 21
Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC® Protein
7:30am
8-K
EX-10.1
vdzlkmoknkbwg4lqz9
22 Jul 21
Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC® Protein
7:30am
8-K
EX-99.1
zlkhwvbv
4 May 21
Arvinas Reports First Quarter 2021 Financial Results and Provides Corporate Update
4:02pm
8-K
EX-99.1
g3t wu2rfgsfp1
1 Mar 21
Arvinas Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
4:03pm
8-K
EX-99.1
5n4gkcg kbvmyo
18 Dec 20
Arvinas, Inc. Announces Pricing of $400 Million Public Offering of Common Stock
6:30am
424B5
l0551
16 Dec 20
Prospectus supplement for primary offering
4:01pm
424B5
8qe77h2a a1
14 Dec 20
Prospectus supplement for primary offering
4:48pm
S-3ASR
mr4il qlf
14 Dec 20
Automatic shelf registration
4:02pm
8-K
EX-99.1
61vf7
14 Dec 20
Regulation FD Disclosure
7:30am
8-K
EX-99.2
spj679 mgu
14 Dec 20
Regulation FD Disclosure
7:30am
8-K
EX-99.1
6frvyeoq
5 Nov 20
Arvinas Reports Third Quarter 2020 Financial Results and Provides Corporate Update
7:31am